Insmed (INSM) - Breakout Opportunity 📌 Insmed ( NASDAQ:INSM ) – Breakout Opportunity
Insmed is a clinical-stage biopharmaceutical company focused on serious and rare lung diseases. The stock more than doubled in May 2024 following positive Phase 3 results for its drug Brensocatib. The FDA has granted Priority Review, with a PDUFA
Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−5.5 EUR
−882.68 M EUR
351.33 M EUR
178.06 M
About Insmed Incorporated
Sector
Industry
CEO
William H. Lewis
Website
Headquarters
Bridgewater
Founded
1988
FIGI
BBG01TNY3323
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
INSM - June 24 Qullamaggie Breakout and Episodic Pivot15 June
Price surfing the 10SMA and making lower highs
There are two large momentum candles bringing price above the consolidation.
It was also one of the rare stocks that was green while the broader market was red
Risk
I know the reason for the new pricing but I am unable to determine if it is so
Insmed Catapults 113% on Positive ASPEN Study ResultsInsmed ( NASDAQ:INSM ), a biotech company, has successfully developed a lung disease drug, brensocatib, which has been shown to significantly reduce the frequency of respiratory symptoms such as chronic cough in a late-stage study. The drug, which is expected to be launched in mid-2025, is expected
Insmed Incorporated (INSM: NASDAQ)Insmed Incorporated (INSM), a biopharmaceutical company, is showing positive developments in its product portfolio. The company reiterated its 2023 guidance, expecting revenue between $295-305 million, with strategic plans to expand the use of its ARIKAYCE product.
Encouraging Phase 2 data for its
See all ideas
An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Related stocks
Frequently Asked Questions
The current price of 1INSM is 60.0 EUR — it has decreased by −3.13% in the past 24 hours. Watch INSMED INC stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on MIL exchange INSMED INC stocks are traded under the ticker 1INSM.
1INSM stock hasn't changed in a week, the month change is a 1.64% rise, over the last year INSMED INC has showed a −1.64% decrease.
We've gathered analysts' opinions on INSMED INC future price: according to them, 1INSM price has a max estimate of 96.73 EUR and a min estimate of 78.27 EUR. Watch 1INSM chart and read a more detailed INSMED INC stock forecast: see what analysts think of INSMED INC and suggest that you do with its stocks.
1INSM reached its all-time high on May 2, 2025 with the price of 64.0 EUR, and its all-time low was 61.0 EUR and was reached on Apr 25, 2025. View more price dynamics on 1INSM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
1INSM stock is 3.33% volatile and has beta coefficient of 0.85. Track INSMED INC stock price on the chart and check out the list of the most volatile stocks — is INSMED INC there?
Today INSMED INC has the market capitalization of 10.85 B, it has increased by 0.29% over the last week.
Yes, you can track INSMED INC financials in yearly and quarterly reports right on TradingView.
INSMED INC is going to release the next earnings report on May 8, 2025. Keep track of upcoming events with our Earnings Calendar.
1INSM earnings for the last quarter are −1.28 EUR per share, whereas the estimation was −1.13 EUR resulting in a −12.74% surprise. The estimated earnings for the next quarter are −1.24 EUR per share. See more details about INSMED INC earnings.
INSMED INC revenue for the last quarter amounts to 100.89 M EUR, despite the estimated figure of 98.61 M EUR. In the next quarter, revenue is expected to reach 85.14 M EUR.
1INSM net income for the last quarter is −227.53 M EUR, while the quarter before that showed −198.06 M EUR of net income which accounts for −14.88% change. Track more INSMED INC financial stats to get the full picture.
No, 1INSM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 7, 2025, the company has 1.27 K employees. See our rating of the largest employees — is INSMED INC on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. INSMED INC EBITDA is −749.17 M EUR, and current EBITDA margin is −213.24%. See more stats in INSMED INC financial statements.
Like other stocks, 1INSM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade INSMED INC stock right from TradingView charts — choose your broker and connect to your account.